0000000001264602

AUTHOR

Dirk Strumberg

showing 3 related works from this author

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-contr…

2014

1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...

OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Efficacy and Safety of First-Line Bevacizumab (BEV) Combined with Paclitaxel (PAC) According to Age: Subpopulation Analysis of a Large, Multicenter, …

2009

Abstract Background: In three randomized phase III trials (E2100, AVADO, RIBBON-1), the combination of Bev with taxane-based therapy significantly improved PFS and response rate versus taxane alone in HER2-negative MBC. Subpopulation analysis of AVADO suggested that the magnitude of the benefit derived from Bev was similar in older and younger pts (≥65 vs <65 years). To gain further information on the safety and efficacy of first-line Bev–pac in older pts treated in the real-life setting, we conducted a subpopulation analysis of data from an ongoing multicenter non-interventional study initiated after the approval of Bev in Germany. Materials and methods: Pts who had received no prio…

OncologyCancer ResearchChemotherapymedicine.medical_specialtyTaxaneBevacizumabbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)Cancermedicine.diseaseMetastatic breast cancerlaw.inventionDiscontinuationSurgeryOncologyRandomized controlled triallawInternal medicinemedicinebusinessmedicine.drugCancer Research
researchProduct

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-bli…

2019

Abstract Background This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in patients with metastatic or locally advanced HER2-negative breast cancer. Patients and methods Patients were randomized 1:1 to receive docetaxel 100 mg/m2 on day 1 every 3 weeks in combination with sorafenib 400 mg bid or placebo on days 2–18 of each cycle until tumor progression, or unacceptable toxicity. Sorafenib/placebo could be continued at the investigator's discretion if docetaxel was stopped due to toxicity. Primary endpoint was progression free surv…

OncologySorafenibAdultmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentPhases of clinical researchAngiogenesis InhibitorsBreast NeoplasmsDocetaxelurologic and male genital diseasesPlaceboDrug Administration Schedule03 medical and health sciences0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalneoplasmsAgedAged 80 and overChemotherapyTaxanebusiness.industryGeneral MedicineMiddle AgedSorafenibmedicine.diseaseMetastatic breast cancerProgression-Free SurvivalTreatment OutcomeDocetaxel030220 oncology & carcinogenesisSurgeryFemalebusinessmedicine.drugBreast (Edinburgh, Scotland)
researchProduct